A proposed steroid card model for palliative care patients

Abstract

Background. Poor medication compliance and control may diminish the effectiveness of the prescribed therapy and might threaten the patient's health. It is a substantial issue in palliative care as almost one-third of patients fail to conform to their therapeutic regimens. Non-compliance may lead to more admissions, longer stay at hospital and more short-term and long-term morbidity and mortality.

Purpose. Tools have to be implemented to limit non-compliance and ensure that patients are able, with encouragement and supervision, to monitor their treatment progress. Medication card is an excellent candidate, since it retains the essential information of the patient, doctor and the prescribed drug, and it also provides convenience, as patients are able to check their progress in real-time, and keep an eye on potential side effects and complications. This paper describes a model created of patient-version of steroids medication card that fulfill the abovementioned goal and provide this service to the palliative care patients. **Methods**. The research was guided and supervised by palliative care specialists and nurses, and I approached multiple patients to calibrate the language and structure for simplicity and clarity. Furthermore, I reviewed official medication card forms produced by major hospices in order to configure the appropriate composition and format of the card. This work is expected to facilitate control and monitoring of steroid regimens palliative care settings.

Medycyna Paliatywna w Praktyce 2016; 10, 4: 149–154

Key words: medications, steroids, palliative care, patient safety

Introduction

Palliative care is the branch of medicine that specialises in managing people with serious and terminal illnesses, and their families, by providing relief from physical and psychological symptoms, primarily pain and stress [1]. The main objective of care is to improve their quality of life and preserve their dignity as much as possible [2]. During therapeutic management, palliative care practitioners prescribe a myriad of medications that are known to have serious side effects, such as opioids, steroids and anticonvulsants. It is worth noting that palliative care patients typically have advanced diseases and their health conditions are usually much poorer than the majority of patients. Consequently, monitoring such clients for potential adverse effects and complications as well as keeping a tight and attentive control on the dosage and compliance are imperative and essential role in being a palliative care practitioner. It is evidently not sufficient to rely only on observable physical and mental deviations or counting solely on the patient's self-reporting. That is because side effects might not be plainly obvious to palliative care practitioners and patients alike, and on the other hand, patients are certainly prone to forget and neglect such changes, or might interpret them as an expected progression of the disease. Therefore, a tool devised to ensure

Corresponding address: Muath Alduhishy 4/15 Parkside Place, Norman Gardens QLD 4701 Australia tel: +61412203139 e-mail: dr.alduhishy@gmail.com Medycyna Paliatywna w Praktyce 2016; 10, 4, 149–154 Copyright © Via Medica, ISSN 1898–0678 patients and practitioners' attention and vigilance towards adverse effect and complications has to be implemented in such settings. Medication cards, that contain essential information about the patient and the prescribed drug, can be very helpful here, especially for those on a long-term course of potentially harmful classes of drugs, which steroids is an obvious example in the domain of palliative care [3]. Steroids or corticosteroids are used commonly in palliative care to alleviate specific and non-specific symptoms related to diseases like advanced malignancies. A few types of corticosteroids are used in palliative care, namely Dexamethasone and Prednisolone, and both have variable efficacy. The indications for corticosteroids use include, for example, spinal cord compression and elevated intracranial pressure as well as pain, nausea and malaise [4]. The widespread and prolonged use of steroids has inevitably led to an increase in the prevalence and impact of its side effects, both major and minor. These include disruption of innate hormone secretion in the hypothalamus-pituitary-adrenal (HPA) axis, as well as sodium and water retention, immunosuppression, edema in the extremities, psychological changes, hypertension, hyperglycemia, and skin changes. Furthermore, corticosteroids have contraindications with numerous drugs that are prescribed frequently, such as particular classes of antivirals and antibiotics. They should also be avoided, or at least reconsidered, in a number of medical conditions, such as diabetes mellitus and active infection, as they will most likely aggravate the disease symptoms and signs in the affected person [5].

Following the aforementioned facts, I started working on a steroid medication card model while working at the palliative care services in the Royal Brisbane Hospital. This card has to be written in lay-language, as it will be chiefly directed to and managed by the patients, and should contain their personal information, exhaustive details about the prescribed drug, and the prescribing doctor's contact information. I worked under the supervision and advice of the palliative care specialists and nurses. They offered me a considerable help to generate an appropriate structure and plan starting from the initial scheme as seen in the appendix (Fig.1).

Material and methods

The steroid medication card that was devised here has been initially inspired from a doctor-oriented Steroid Proforma acquired from the Princess Alexandra hospital, which was produced in 2008 by a coalition of hospices and palliative care providers in the United Kingdom (Fig. 2) and also a Steroid Replacement handout produced by the Imperial College Healthcare NHS Trust (Fig. 3). Next, as the project progressed, I had multiple meetings with the director of the palliative care services at the Royal Brisbane hospital Dr. Carol Douglas, and the palliative care specialist Dr. Alison Kearney, as well as discussions with the rest of the team members, including palliative care nurses and medical trainees. I also consulted with some of the patients whom the services oversee to gauge the clarity and simplicity of the language and structure. Unlike the two documents that were mentioned in the beginning of this section, which have markedly descriptive and instructive technical structure, my design is much more 'layman-friendly'

Steroids

Steroids are used commonly in palliative medicine for a wide range of applications. They are effective as an adjuvant for pain, neural compression, nausea, etc. However there is significant toxicity assoc with steroids even with short courses; psych, hyperglycaemia, proximal myopathy, oedema etc.

I am concerned that patients are commenced of a wide range of regimes with no clear endpoint and are at significant risk of adverse events especially after discharge form hospital.

Suggest Audit – palliative care pt, not pre-terminal, ? not brain disease

Which regime used Indication PPI cover or not BSL or not Plan to wean Info on discharge as to who should monitor

Figure 1. The initial scheme of the project

Harris Hosp	Discare	PRINCESS ALICE HOSPICE	Guy's and St Thomas' NetS foundation Trust	St Ovisiopher's Hospi 1967-200	- 1	Complete One Column for Each Review of Steroids							
	Presc	ribing Stere	oids in Palliative	e Care		Date: of this follow up							
Complete Once	- For Fa	ch Course of S	Steroids		200					ma			
Complete Once	e FOI La		rting date:	//		Dose: most recent / current	ALL AND ADDRESS OF ADD			^{mg}			
Steroid chosen: Dexamethasone					Steroid Response: overall clinical impression of recent / current benefit attributed to steroids Pragmatic grading response; X is none; V is minimal; V is good; V V is complete								
Patient Label		Prednisolone			Indication 1	is none, - is no	none, is minima, is good, it is complete						
					Indication 2	211							
	Sta		Route: PO S/C			Indication 3							
			rted by: Hospice	Hospital U GP					1				
						Steroid Toxicity: overall clinic Pragmatic grading of toxicity; -	al impression of r is none: + is	recent / current s mild: ++ is m	ide effects attribu oderate: +++ is	ted to steroids s severe			
Indication(s)						Thrush				1.2			
Prior steroids	No 🛛	Yes D Plea	se detail any previous st	eroid use:		Dyspepsia							
Phor steroids					-	Oedema			100 C				
Initial cautions include (circle Y or N) Possible actions (see guidelines)				-	Cushingoid								
Dyspepsia Peptic Ulcer NSAID/Aspirin Y/N Consider stopping NSAID +/- PPI for any symptoms y/N Monitor blood glucose +/- use reduced steroid dose													
Diabetes Y/N			itor oedema		Proximal myopathy								
Heart Fallore			otics +/- defer steroids		Blood glucose problems								
Acute infection Y/N Previous psychosis Y/N			wer +/- reduced steroid of	e	Altered / low mood								
Concurrent phenyte				ts +/- increased steroid		Restlessness			1012				
Describe any	Describe any other				-	Psychosis			199				
relevant caution any initial action						Other(s)	Line and the second						
		Date of first re	eview //	12 18					- · · · · ·				
Describe the p subsequent of	lan for dose		ation of course:		100								
changes		Detail any specific plans:				Steroid Management Plan							
						Advised dose	mg	mg	mg	m			
A statistics of the	aliaiaal			1									
Any additional clinical details not already covered sufficiently						Reason and plans for future dose changes	Nela A						
Patient Informat			nies						-				
Tick and date boxes Steroid Card			ent tient Information Lea			Date of next review	//		//	//-			

Figure 2. Steroid Proforma produced by the Princess Alice Hospice, Harris Hospice Care, Guy's and St Thomas's Foundation and St. Christopher's Hospice in the United Kingdom

as it was aimed to patients so they can participate in the drug monitoring process. At first, the initial draft (Fig. 4) has the title "Steroid Card for Palliative Care", to elucidate the intended purpose, and the caveat "Complete once for each course". It consists of one page that has spaces to be filled pertaining to the prescribed drug specifics, namely its type, starting dosage, frequency, route, indications and whether it has been used before or not. In addition, a space was left for the course plan including when to wean, and a section illustrating the main contraindicated drugs and conditions has been added. The card also asks technical questions directed to the doctor about further clinical details and precautions. Later on, the following issues have been highlighted: 1) Dexamethasone and Prednisolone are the only corticosteroids available for palliative care patients in the hospital. 2) Drug frequency should be left as blank to give more freedom. 3) A space should be provided for the prescribing doctor information. 4) Clinical instructions should be avoided since it is directed to patients not doctors. 5) Writing spaces are too small and thus must be expanded. 6) The major side effects should be included.

Unsurprisingly, when I consulted with a number of palliative care patients they found the first draft to be difficult to read and use.

Next, the steroid card was amended and improved based on the previous suggestions along with a redesigned and enhanced layout. Accordingly, with the assistance of the literature, the major side effects, specifically those that present to patients as observable symptoms, are highlighted in a simple language [5, 6]. The idea is to alert patients so they can contact their doctors when such symptoms manifest. Furthermore, a review table was added on the back of the paper to record the details of every drug review. It encompasses the date of review, response, toxicity, new dose, date of the next review and the reviewing doctor signature. A warning was also annexed to emphesise on patients not to stop taking steroids without consulting their doctors.

Discussion

The final work was completed as pictured in Figure 5. Given the importance of the subject, the design's schema and language were purposefully simplistic in




Figure 3. Steroid Replacement handout produced by the Imperial College Healthcare NHS Trust

order to be visually clear and undistracting. The medication card consists of two pages so it can be printed into a one double-sided sheet of paper making it convenient and easier to carry around. There is a designated space in the upper left corner of the first page to affix the patient label, which has their basic information. However, if the label was not available, the patient can fill his or her own information, specifically the name, number, dates of birth and address. Next, the right side of the first half of the page is assigned to the essential drug details; starting date, type, initial dose, frequency per day, where it was started and the prescribing doctor's contact details. Then, a large table was drawn with this warning on top of it "DON'T STOP taking steroids without consulting with your doctor". Underneath it, there is a space left to write down the indications for taking the medication, and another space to answer the question "Have you used Steroids before?". If the answer was yes, then more questions have to be answered: Why? What type? For how long? and How was the response?. Next, the drug course details have to be written including the date of first review, duration of course and indications for stopping and weaning. Afterward, lists of the main medical conditions and medications that are contraindicated with steroids, and also the major symptoms of adverse effects were charted with the declaration: Please inform your doctor if you are having/taking/experiencing the listed items. At




Figure 4. First draft of the steroid card with the proposed comments and notes

		Row For Eac				-	Steroid Card for Palliative Care						
Date	Response	Toxicity	New Dose	Next Review	Doctor Sign.	Notes	Complete on Starting Date/		each course		Parimer Labol		
.//			ng Tong	//				Medication: Dexamethasone			amber OBI		
.//			mg To mg	//			12.17.1 C 2.37 C	mg		^	ldress:		
.//			ng Tong	//				Frequency per day:					
.11				//			Name of Doctor: Contact Details:	Name of Doctor: Name of Center/Service:					
.//			mg To mg	//				* DON'T STOP taking steroids without consulting with your doctor					
.//			mg To mg	//			Indication(s)						
.//			mg To mg	//									
.//				//			Have you used Steroids before?	υY	'es, please give detail	s 🗆 No			
.//				//			Steronas before?	Wby? What typ					
.1			ng Tong	//				For how How wa					
.//			mg Tomg	//			Plan	Plan Date of first review:// Duration of course:					
.//			ng Tong	//				Indicat	tions for stopping:				
.//				//				Other I	Details:		******		
.//				//			*Please inform	m your doctor if you have any of the following conditions:					
.1			ng To ng				Diabetes				Psychiatric	ondition	
			ng To ng					*Please inform your doctor if you are taking any of the following medications: Non-steroidal anti-inflammatory drugs, such as Aspirin, Ibuprofen, and Naproxen					
-//	-		mg 10 mg	//			Oral contracet		Anticonvulsants		Antibiotics	Antivirals	
1 1			reg To reg	//				*Please inform your doctor if you start having the					
1				//			Ankle s			Agitation	Sore mouth		
1			mg To mg				Vision p	Vision problems		Poor sleep Muscle weakness			
	onse: XN	one;	✓ Minimal;	<pre> √√Good;</pre>	1110	omplete	Who will monitor	r after dis	scharge? Name of Name of States	Doctor: Center/Service:			
•Toxi	city: -No	ne;	+ Mild;	++ Moder	ate: +++ Sev	ere			Contact E	Netails:			

Figure 5. The final form of the steroid card for palliative care patients

the end of the first page, the name of doctor who will monitor the therapy regimen after discharge has to be recorded with their contact details. On the second page that resides in the backside, a large segmented table is drawn to record the progress of therapy by documenting each drug review including the date, response, toxicity, adjusted dose, date of the next review, and the doctor signature.

Conclusions

To conclude, the product of the project conducted here is a steroid card developed under the supervision of experienced palliative care specialists as well as lay-people's validation of the clarity of its language and structure. It encompasses the necessary information to verify the identity of the patient and their doctor along with thorough details of the medication and its therapeutic course. The steroid card offers an excellent tool to monitor patients' compliance and detect if they start to develop any of the major side effects or complications. However, this is not the end of the line. The next step is to conduct a pilot study on a set of patients, while using another set who did not receive this card as controls, and see if this steroid card aids significantly in the patient adherence to the therapy regimen and whether it provides better control and vigilance to side effects and complications. The outcome of the study will confirm the value of such a tool, and it will guide

future decision on using medication cards in palliative care, or even other branches of medical practice.

Conflict of interest

None of the material has been published previously, is under consideration, or has been accepted for publication elsewhere. All persons listed as authors have read and given approval for the submission of the manuscript.

Funding

No financial funding to declare or other relationships that might lead to a conflict of interest.

Reference

- Lafleur J, Oderda G. Methods to Measure Patient Compliance with Medication Regimens. Journal of pain & palliative care pharmacotherapy. 2004; 18(3): 81–87.
- WHO. Definition of Palliative Care. World Health Orgnisation. 2014.
- Finlay I, Jones N, Wyatt P, Neil J. Use of an unstructured patient-held record in palliative care. Palliative Medicine. 1998; 12(5): 397–398.
- Hardy JR, Rees E, Ling J, Burman R, Feuer D, Broadley K, et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliative Medicine. 2001; 15(1): 3–8.
- Shih A, Jackson KC. Role of Corticosteroids in Palliative Care. Journal of Pain and Palliative Care Pharmacotherapy. 2007; 21(4): 69–76.
- Buchman AL. Side effects of corticosteroid therapy. Journal of clinical gastroenterology. 2001; 33(4): 289–294.